우르소디올
Ursodiol
Ursodeoxycholic acid
다른 이름: Actigall · URSO 250 · URSO Forte · acidum ursodeoxycholicum · UDCA · ursodesoxycholic acid
VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
동물 종별 용량
🌎 NA — North America🌍 EU — Europe
개
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Adjunctive treatment of chronic hepatitis | 5-15 mg/kg PO divided q12h | PO | q12h | — | 🌎 NA |
| Cholestatic liver disease, cholangitis/cholangiohepatitis, chronic hepatitis, and copper-associated hepatopathy | 10-15 mg/kg PO once daily | PO | q24h | — | 🌎 NA |
| Chronic active hepatitis, fibrosis and cirrhosis | 11-15.4 mg/kg PO either once daily or divided twice daily | PO | q12h-q24h | — | 🌎 NA |
- Adjunctive treatment of chronic hepatitis: With immunosuppressive therapy. Note: Use of this drug at this dose is preliminary, but promising.
- Cholestatic liver disease, cholangitis/cholangiohepatitis, chronic hepatitis, and copper-associated hepatopathy: Safe and potentially beneficial.
- Chronic active hepatitis, fibrosis and cirrhosis: May use as primary or adjunctive therapy.
고양이
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Cholestatic liver disease, cholangitis/cholangiohepatitis, chronic hepatitis, and copper-associated hepatopathy | 10-15 mg/kg PO once daily | PO | q24h | — | 🌎 NA |
| Chronic active hepatitis, fibrosis, and cirrhosis | 11-15.4 mg/kg PO either once daily or divided twice daily | PO | q12h-q24h | — | 🌎 NA |
| Adjunctive treatment of chronic hepatitis | 10 mg/kg/day PO | PO | q24h | — | 🌎 NA |
- Cholestatic liver disease, cholangitis/cholangiohepatitis, chronic hepatitis, and copper-associated hepatopathy: Safe and potentially beneficial.
- Chronic active hepatitis, fibrosis, and cirrhosis: May use as primary or adjunctive therapy. Cats usually get 1/6th of a capsule mixed with a small amount of food. Cats may still eat their food even if drug is sprinkled on top.
새
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Adjunctive treatment of liver disease | 10-15 mg/kg PO once daily | PO | q24h | — | 🌎 NA |
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
개요
우르소디올은 천연 친수성 담즙산으로 주로 개와 고양이의 간담도 질환에 대한 보조 치료제로 사용됩니다. 간 보호, 담즙 분비 촉진 및 면역 조절 특성이 있어 독성 담즙산에 의한 간세포 파괴를 줄이고 콜레스테롤 담석 용해를 돕습니다.
작용 기전
Ursodiol exerts its effects through multiple hepatoprotective and choleretic pathways:
- Cholesterol Reduction: Suppresses hepatic synthesis and secretion of cholesterol and decreases intestinal absorption of cholesterol.
- Gallstone Solubilization: By reducing cholesterol saturation in the bile, it allows the solubilization of cholesterol-containing gallstones.
- Choleretic Effect: Increases bile flow, which helps flush toxic bile acids from the liver.
- Cytoprotection: Reduces the hepatocyte toxic effects of endogenous hydrophobic bile salts (e.g., lithocholate, deoxycholate) by decreasing their detergent action on cell membranes, thereby protecting hepatic cells from apoptosis and necrosis.
안전성·주의사항
금기사항
- Rabbits and other hindgut fermenters (converted to toxic lithocholic acid)
- Biliary obstruction
- Biliary fistulas
- Cholecystitis
- Pancreatitis
- Cholangitis (if complete obstruction is present)
부작용
- Diarrhea
- Gastrointestinal upset (rare)
주의
Ursodiol is strictly contraindicated in rabbits and hindgut fermenters. Use with caution in patients with complications associated with gallstones (e.g., biliary obstruction, cholecystitis). While useful for chronic liver disease, some patients may experience further impairment of bile acid metabolism. It will not dissolve calcified radiopaque stones or radiolucent bile pigment stones.
약물 상호작용
May bind to ursodiol, thereby reducing its efficacy
May bind to ursodiol, thereby reducing its efficacy
Theoretical concern that chronic administration in cats may lead to taurine deficiency
모니터링
- Efficacy via ultrasonography for gallstones
- Improved liver function tests for chronic hepatic disease
- SGPT/SGOT (AST/ALT) on a routine basis
약동학
흡수
Well absorbed from the small intestine after oral administration (up to 90% in humans).
분포
Enters the portal circulation. Ursodiol detected in the systemic circulation is highly bound to plasma proteins.
대사
Extracted by the liver and conjugated with either taurine or glycine, then secreted into the bile. Undergoes entero-hepatic cycling and bacterial degradation.
배설
Mostly eliminated in the feces after being oxidized or reduced to less soluble compounds. Very little is detected in the urine.
과다투여
Overdosage of ursodiol would most likely cause diarrhea.
Treatment:
- Supportive therapy.
- Oral administration of an aluminum-containing antacid (e.g., aluminum hydroxide suspension) to bind the drug.
- Gastric emptying (if large overdose occurred recently) with concurrent administration of activated charcoal or cholestyramine suspension.
제품
제형
- Oral Capsules
- Oral Tablets
인용의약품
- Ursodiol Oral Capsules: 300 mg (Actigall & generic)
- Ursodiol Oral Tablets: 250 mg & 500 mg (URSO 250 & URSO Forte; generic)
규제 현황
규제 데이터 없음: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
보관·안정성
Store capsules at room temperature (15-30°C) in tight containers unless otherwise specified by the manufacturer.
보호자 정보
담즙이나 췌장액이 있을 때 약물이 더 빨리 용해되므로 음식과 함께 투여하십시오. 간 질환 관리는 장기적인 과정이므로 수의사와 상의 없이 약물 투여를 중단하지 마십시오. 설사나 위장 장애 징후가 나타나면 수의사에게 알리십시오.
VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.